アローヘッドのRNA薬ARO-INHBEとARO-AL-K7は,健康上の深刻な問題のないティルゼパチドと併用したときは,肥満患者の早期減量と脂肪減少を示した. Arrowhead's RNAi drugs ARO-INHBE and ARO-ALK7 showed strong early weight loss and fat reduction in obese patients when combined with tirzepatide, with no serious safety issues.

アローヘッド医薬品は,2つのRNA療法,ARO-INHBE及びARO-ALK7の検査結果から,早期に有望な結果が出たと報告している. Arrowhead Pharmaceuticals reported promising early results from Phase 1/2a trials of two RNAi therapies, ARO-INHBE and ARO-ALK7, for treating obesity. ティルゼパチドと併用したARO- INHBEは,ティルゼパチド単独投与と比較して体重減少をほぼ2倍,内臓脂肪,全脂肪,肝脂肪を3倍に減らし,体重減少は最大9. 4%,肝脂肪は77%まで減りました. When combined with tirzepatide, ARO-INHBE led to nearly double the weight loss and tripled reductions in visceral, total, and liver fat compared to tirzepatide alone, with up to 9.4% weight loss and 77% liver fat reduction in patients with type 2 diabetes. ARO-INHBEも、アクティヴィン Eレベルを著しく下げて,低屈の組織を強化した. ARO-INHBE also significantly lowered Activin E levels and increased lean tissue. ARO-ALK7は,服用性遺伝子シリンゼーション,シリンダー脂肪の14.11%減少. ARO-ALK7 showed dose-dependent gene silencing and a 14.1% reduction in visceral fat. 治療は両方がよく耐えるものであったが,安全性に関する重大な懸念はなかった. Both therapies were well-tolerated with no serious safety concerns. 結果は前項で,2026年には追加データが予想される. Results are preliminary, and additional data are expected in 2026.